TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02385877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]4F-MHPG
Description: IV injection of \[18F\]4F-MHPG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]4F-MHPG
Description: IV injection of \[18F\]4F-MHPG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]3F-PHPG
Description: IV injection of \[18F\]3F-PHPG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]3F-PHPG
Description: IV injection of \[18F\]3F-PHPG
Study: NCT00735657

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: needle
Description: Peribulbar blockade with standard (25 mm) needle
Study: NCT02476591

Intervention type: BEHAVIORAL
Intervention: Charge Transparency
Description: Providers caring for patients in the Charge Transparency cohort will be given access to patient specific charge data on a daily basis via an interactive dashboard which allows for full charge transparency to patients admitted to the Vanderbilt ICUs
Study: NCT03136770

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CK-30
Description: Compound K 600 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CK-30
Description: Compound K 600 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red ginseng extracts
Description: Red ginseng extracts 2.94 g
Study: NCT00735657

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: needle
Description: Peribulbar blockade with short (12.5 mm) needle
Study: NCT03136770

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red ginseng extracts
Description: Red ginseng extracts 2.94 g
Study: NCT02664532

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Miller group
Description: Miller blade was used for laryngoscopy

Intervention type: OTHER
Group type: OTHER
Intervention: Macintosh group
Description: Macintosh blade was used for laryngoscopy
Study: NCT01085058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenograstim
Study: NCT01594294

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AOSEPT® Plus contact lens solution
Description: Hydrogen peroxide-based cleaning and disinfection system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReNu MultiPlus® contact lens solution
Description: Polyaminopropyl biguanide (PHMB) preserved multipurpose solution

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Etafilcon A contact lenses
Description: Hydrogel contact lenses worn on a daily wear basis for 14 days (Screening Phase) and 3 months (Investigational Phase). During the Investigational Phase, the contact lenses lenses were worn a minimum of six hours per day, 5 days per week, with a fresh pair dispensed every 2 weeks.

Intervention type: DEVICE
Group type: OTHER
Intervention: Etafilcon A contact lenses
Description: Hydrogel contact lenses worn on a daily wear basis for 14 days (Screening Phase) and 3 months (Investigational Phase). During the Investigational Phase, the contact lenses lenses were worn a minimum of six hours per day, 5 days per week, with a fresh pair dispensed every 2 weeks.
Study: NCT01678872

Intervention type: DRUG
Group type: OTHER
Intervention: RetinoStat
Description: Long Term Follow up of patients who received RetinoStat in a previous study
Study: NCT00925886

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acrysof Toric one-piece intraocular lens
Description: Cataract Surgery with a intraocular lens implantation
Study: NCT00242359

Intervention type: DRUG
Group type: OTHER
Intervention: omalizumab
Study: NCT03718598

Intervention type: BEHAVIORAL
Intervention: Tendon and Nerve Gliding Exercises
Description: Tendon and Nerve Gliding Exercises: The tendon slip exercises used in this study were performed in five different positions, namely flexion, flat, hook, punch, table top and flat punch positions. Nerve-gliding exercises were performed by moving the fingers and wrists in six different positions, focusing on the median nerve consisting of all the disease grip, finger lengthening, wrist extension, thumb extension, forearm supination and gentle gentle gait. Instructions were given to make 10 sets of exercises in 3 sets, written and verbal, in order to have e exercises for all patient's tendons and nerves shifting exercises. Brochures were also provided explaining the exercises.

Intervention type: BEHAVIORAL
Intervention: Tendon and Nerve Gliding Exercises
Description: Tendon and Nerve Gliding Exercises: The tendon slip exercises used in this study were performed in five different positions, namely flexion, flat, hook, punch, table top and flat punch positions. Nerve-gliding exercises were performed by moving the fingers and wrists in six different positions, focusing on the median nerve consisting of all the disease grip, finger lengthening, wrist extension, thumb extension, forearm supination and gentle gentle gait. Instructions were given to make 10 sets of exercises in 3 sets, written and verbal, in order to have e exercises for all patient's tendons and nerves shifting exercises. Brochures were also provided explaining the exercises.
Study: NCT02834598

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high-density electroencephalography
Description: Cerebral measurements from high-density electroencephalography while standard and deviant sounds are presented to the participant.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-density electroencephalography
Description: Cerebral measurements from high-density electroencephalography while standard and deviant sounds are presented to the participant.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high-density electroencephalography
Description: Cerebral measurements from high-density electroencephalography while standard and deviant sounds are presented to the participant.
Study: NCT02089217

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Description: Carotid endarterectomy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid Stenting (CAS)
Description: Carotid stenting

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Medical Management - no CEA
Description: Intensive Medical Management alone - no CEA
Study: NCT00735657

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pars Plana Vitrectomy
Description: Peribulbar block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pars Plana Vitrectomy
Description: Peribulbar block
Study: NCT02982226

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ReNu Injection
Description: ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
Study: NCT01594294

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etafilcon A contact lenses
Description: Hydrogel contact lenses worn on a daily wear basis for 14 days (Screening Phase) and 3 months (Investigational Phase). During the Investigational Phase, the contact lenses lenses were worn a minimum of six hours per day, 5 days per week, with a fresh pair dispensed every 2 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon B contact lenses
Description: Silicone hydrogel contact lenses worn on a daily wear basis for 30 days (Screening Phase) and 3 months (Investigational Phase). During the Investigational Phase, the contact lenses lenses were worn a minimum of six hours per day, 5 days per week, with a fresh pair dispensed monthly.

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B contact lenses
Description: Silicone hydrogel contact lenses worn on a daily wear basis for 30 days (Screening Phase) and 3 months (Investigational Phase). During the Investigational Phase, the contact lenses lenses were worn a minimum of six hours per day, 5 days per week, with a fresh pair dispensed monthly.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lotrafilcon B contact lenses
Description: Silicone hydrogel contact lenses worn on a daily wear basis for 30 days (Screening Phase) and 3 months (Investigational Phase). During the Investigational Phase, the contact lenses lenses were worn a minimum of six hours per day, 5 days per week, with a fresh pair dispensed monthly.

Intervention type: DEVICE
Group type: OTHER
Intervention: COMPLETE® MPS Easy Rub® Formula contact lens solution
Description: PHMB 0.0001% and poloxamer 0.05% multipurpose solution
Study: NCT00305253

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-pneumatic Anti-shock Garment (NASG)
Description: In the Post-Intrevention phase of the study, the NASG will be used when a patient meets the study criteria.
Study: NCT04406051

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: norepinephrine infusion and colloid preloading (NOR-COL)
Description: in parturients allocated to the NOR-COL group, a norepinephrine infusion will be started as soon as spinal anesthesia is initiated. This group will also receive 5 mL/kg of colloid infusion prior to the initiation of spinal anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: norepinephrine infusion and crystalloid co-loading (NOR-CRYST)
Description: in parturients allocated to the NOR-CRYST group, a norepinephrine infusion will be started as soon as spinal anesthesia is initiated. This group will also receive 10 mL/kg of crystalloid infusion simultaneously with the initiation of spinal anesthesia
Study: NCT02251444

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: outpatient rehabilitation program

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy
Study: NCT04156932

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: uterine artery closure
Description: Interruption the uterine blood flow by closing the uterine artery at its cervical-isthmic part or at its origin.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: uterine artery closure
Description: Interruption the uterine blood flow by closing the uterine artery at its cervical-isthmic part or at its origin.
Study: NCT02982226

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid Injection
Description: Corticosteroids are considered a standard of care for treatment of Plantar Fasciitis
Study: NCT01480167

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vertebral Augmentation (STABILIT)
Description: Vertebral Augmentation with the STABILIT Vertebral Augmentation System

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-operative Management
Description: Conservative Care
Study: NCT03848455

Intervention type: DIAGNOSTIC_TEST
Intervention: genetic diagnosis
Description: The venous blood of the two groups of patients was taken for genetic testing, and the expression levels of PPP2CA, PPP3CB, SYNJ1, NSF and CYCS were extracted by pre-processing the genetic data of PD and non-PD patients.

Intervention type: DIAGNOSTIC_TEST
Intervention: genetic diagnosis
Description: The venous blood of the two groups of patients was taken for genetic testing, and the expression levels of PPP2CA, PPP3CB, SYNJ1, NSF and CYCS were extracted by pre-processing the genetic data of PD and non-PD patients.
Study: NCT02433405

Intervention type: BIOLOGICAL
Intervention: Fetuin-A
Description: Acute phase protein

Intervention type: BIOLOGICAL
Intervention: Fetuin-A
Description: Acute phase protein

Intervention type: BIOLOGICAL
Intervention: Fetuin-A
Description: Acute phase protein
Study: NCT02523820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate
Description: Flixotide 1 mg + NSS upto 4 ml nebulized after extubation. Record vital signs and modified Westley score at 0, 15, 30, 60 min and 2,4,6 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NSS 4 ml nebulized after extubation. Record vital signs and modified Westley score at 0, 15, 30, 60 min and 2,4,6 hours
Study: NCT04480242

Intervention type: DRUG
Intervention: Inhaled Corticosteroids (ICs)
Description: Any corticosteroid (beclomethasone, budesonide, ciclesonide, fluticasone propionate, fluticasone furoate, mometasone, and triamcinolone) prescribed by the pediatrician as an inhaled controller medication, for daily management of asthma. The daily dose of ICs prescribed will be translated into beclomethasone equivalent.

Intervention type: DRUG
Intervention: Fixed-Dose Combination of Inhaled Corticosteroids and Long- Acting Beta-agonist (ICs/LABA)
Description: Beclomethasone/formoterol, budesonide/formoterol, fluticasone furoate/vilanterol, fluticasone propionate/formoterol, fluticasone propionate/salmeterol, and mometasone/formoterol. Any of these combinations prescribed by the pediatrician as an inhaled controller medication, for daily management of asthma.

Intervention type: DRUG
Intervention: Other treatments
Description: Low-dose oral corticosteroids, long-acting muscarinic antagonist (tiotropium), low-dose macrolides (azithromycin), leukotrienes receptor antagonists (i.e. montelukast), or biologic agents (i.e. omalizumab).

Intervention type: DRUG
Intervention: Inhaler device
Description: Pressurized metered-dose inhalers (pMDIs), Breath-actuated pMDIs, Dry powder inhalers (DPIs), Nebulizers, Soft Mist Inhalers.

Intervention type: BEHAVIORAL
Intervention: Regularly monitoring of the Inhalation technique through mobile app
Description: App users are randomized within each pediatrician into two groups of equal size defined within the subsample recruited, so that 50% of the participants are allocated to answer the inhalation techniques, and the other 50% are allocated to answer the environment support scales. Once the app is downloaded, at month 2 and every 6 months thereafter the intervention group answers the inhalation techniques scale (group 1) and the control group answers the environment support scale (group 2).
Study: NCT02300428

Intervention type: DIETARY_SUPPLEMENT
Intervention: oral iron
Description: BNF code for section 9.1.1.1 (Oral iron preparations for iron-deficiency anaemias)

Intervention type: DIETARY_SUPPLEMENT
Intervention: oral iron
Description: BNF code for section 9.1.1.1 (Oral iron preparations for iron-deficiency anaemias)
Study: NCT02604862

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FIB ONE
Description: FIB ONE will be administered to each patient during a bronchoscopy procedure. Fibre-based endomicroscopy and two types of viewer software will be used to detect FIB ONE signal in the lung.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FIB ONE
Description: FIB ONE will be administered to each patient during a bronchoscopy procedure. Fibre-based endomicroscopy and two types of viewer software will be used to detect FIB ONE signal in the lung.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AZD1236
Description: AZD1236 will be delivered at microdose concentrations and is thus considered to be unable to exert any pharmacologic effect outside the area of administration and unlikely to cause an adverse reaction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AZD1236
Description: AZD1236 will be delivered at microdose concentrations and is thus considered to be unable to exert any pharmacologic effect outside the area of administration and unlikely to cause an adverse reaction.
Study: NCT02748941

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HITS quantification, Ultrasound examinations, High Resolution MRI
Description: Simultaneously measure the occurrence of the event (ischemic stroke) and the characteristics of the atheromatous plaque~Description of different modalities:~HITS quantification~Ultrasound examinations:~* Ulceration \>2 mm~* Plaque thickness~* GSM: computer analysis after normalization of most informative longitudinal view (image with maximum plaque area) using Photoshop~* CEUS: plaque vascularization detection after bolus injection of SONOVUE on a video recording from the injection of the contrast (Vuebox - Bracco imaging)~High Resolution MRI:~* Stenosis severity, intraplaque hemorrhage, large lipid-rich necrotic core, ulceration or cap rupture and Brain MRI will be evaluated~* Quantification of shear stresses (Pa) on the surface of the plaque~mi-RNA identification and quantification
Study: NCT02456181

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: JumpMath
Study: NCT04198324

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closure of the uterus with endometrium at the time of cesarean
Description: Closure of the uterus at the time of primary cesarean will be performed with suturing the endometrium.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Closure of the uterus without endometrium at the time of cesarean
Description: Closure of the uterus at the time of primary cesarean will be performed without suturing the endometrium.
Study: NCT02568124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02717065

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tone
Description: Band-limited white noise stimulus or frequency-matched tone presented at a comfortable loudness level via headphones or earphones.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video
Description: Silent video recording of a person speaking or a still face with an expanding circle over the mouth presented on a computer or tablet screen.
Study: NCT01248494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235
Description: * Dose level 1: 400mg PO BID~* Dose level -1: 400mg PO in AM and 200mg PO in PM~* Dose level -2: 200mg PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM 120
Description: * Dose Level 1: BKM120, 100 mg PO daily~* Dose level -1: BKM120, 80 mg PO daily~* Dose Level -2: BKM120, 60 mg PO daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: All levels: 2.5mg/day PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: All levels: 2.5mg/day PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: All levels: 2.5mg/day PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: * Dose Level 1: BKM120, 100 mg PO from Mondays through Fridays, weekly~* Dose level -1: BKM120, 80 mg PO from Mondays through Fridays, weekly~* Dose Level -2: BKM120, 60 mg PO from Mondays through Fridays, weekly
Study: NCT02694627

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MenCare+/Bandebereho fathers'/couples' group education
Description: MenCare+/Bandebereho is a 3 year project to engage men in maternal, newborn and child health (MNCH) and in sexual and reproductive health in Rwanda. A core component of the project is fathers'/couples' group education. The target participants are first-time parents or parents of young children living in 16 rural and semi-urban sectors selected by the implementing partner in collaboration with local authorities. The MenCare+/Bandebereho fathers'/couples' group education engages men in 15 weekly sessions of group discussion, critical reflection and interactive activities led by a trained facilitator using a curriculum developed by RWAMREC and Promundo and approved by the Rwandan Ministry of Health, adapted from the Program P Manual. Men's partners participate in 6-8 sessions. The sessions focus on men's role in MNCH, family planning, sharing household responsibilities, intimate partner violence, conflict resolution, family budgeting, and gender equality.
Study: NCT02027168

Intervention type: OTHER
Intervention: CPA
Description: Site specific, patient centered manual physical therapy regimen focused on restoring function to the entire body
Study: NCT00022971

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Apolizumab
Description: Apolizumab IV on Day 1. Administer weekly for 4 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab IV 24-36 hours after Apolizumab ends. Administer weekly for 4 weeks
Study: NCT04065373

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ivWatch Model 400 with SmartTouch and fiber optic sensor
Description: The ivWatch Model 400 with SmartTouch or fiber optic sensor monitored tissue at common IV sites over a 24 hour period.
Study: NCT01393756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide and R-CHOP
Description: Lenalidomide dose administered orally during 14 days in combination with 6 courses of fixed doses of R-CHOP 21.
Study: NCT01235286

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: remote ischemic preconditioning
Description: A standardized location for microcirculatory assessment was determined on the left leg of each participant between the proximal and distal third of a drawn line between the anterior superior iliac spine and the lateral aspect of the Patella.~The healthy subjects had to rest before starting data assessment in a horizontal position for 15 minutes. The probe was taped on the left upper leg in a standardized manner after localizing the measuring point. A blood pressure cuff was applied on the contralateral upper arm. Baseline data was assessed over 5 minutes before starting remote ischemia. Three circles of a five minute ischemia were applied at the contralateral right upper arm at suprasystolic levels. Parameters of microcirculation were assessed continuously over time. Microcirculation during the reperfusion phase was ascertained over 10 minutes after first and second remote ischemia and 15 minutes after the third remote ischemia.
Study: NCT03765255

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In the Know: sexual health education
Description: The in-person sessions include modules on: sexual and reproductive health (2 hours - anatomy, gender and sexual orientation, pregnancy, contraception, sexually transmitted infections); healthy relationships and life skills (2 hours - communication and negotiation, consent, violence, online dating, goal setting, strengths); and educational and career success (2 hours - educational and career options, applying for scholarships and financial aid, job readiness, resume preparation, interview skills). The app includes: online referrals, personal life plans/goal setting, text message reminders, quizzes, and other resources.
Study: NCT00671580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PZ-601
Description: 750 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PZ-601
Description: 1000 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: as directed